CMX001 is an orally administered lipid conjugate of the synthetic nucleotide analog
cidofovir (CDV). The conjugate is believed to be absorbed in the small intestine then
delivered to target organs throughout the body where it crosses cell membranes by
facilitated and passive diffusion. Inside the cell, CMX001 is cleaved by intracellular
phospholipases to release CDV which is converted to the active antiviral agent,
CDV-diphosphate (CDV-PP), by intracellular anabolic kinases. Adults and adolescents,
regardless of viral infection/disease, will have a maximum weekly dose of 200 mg i.e., 200
mg once weekly OR 100 mg twice weekly; not to exceed 4mg/kg total weekly dose. Pediatric
subjects (< 12 years), regardless of viral infection/disease, will have a maximum weekly
dose of 4 mg/kg i.e., 4 mg/kg once weekly OR 2 mg/kg twice weekly.
Stanford is currently not accepting patients for this trial.
For more information, please contact Julia Buckingham, (650) 736 - 1556.
View full details